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Neurobiology of Disease
HIV-1 Tat Triggers Nuclear Localization of ZO-1 via Rho
Signaling and cAMP Response Element-Binding Protein
Activation
Yu Zhong, Bei Zhang, Sung Yong Eum, andMichal Toborek
Molecular Neuroscience and Vascular Biology Laboratory, Department of Neurosurgery, University of Kentucky Medical Center, Lexington, Kentucky
40536
The human immunodeficiency virus (HIV)-specific protein trans-activator of transcription (Tat) can contribute to the dysfunction of
brain endothelial cells andHIV trafficking into thebrainbydisrupting tight junction (TJ) integrity at theblood–brainbarrier (BBB) level.
Specific TJ proteins, such as zonula occludens (ZO) proteins, localize not only at the cell– cell borders but are also present in the nuclei.
The objective of the present study was to evaluate the mechanisms and significance of Tat-induced nuclear localization of ZO-1. Treat-
ment of a brain endothelial cell line (hCMEC/D3 cells) with Tat resulted in a decrease in total levels of ZO-1 but significantly upregulated
ZO-1 protein expression in the nuclei. In addition, exposure to Tat stimulatedRho signaling and induced phosphorylation and activity of
transcription factor cAMPresponse element-bindingprotein (CREB), binding sites that havebeen identified in theproximal regionof the
ZO-1 promoter. Interestingly, inhibition of the Rho cascade protected against Tat-induced upregulation of ZO-1 in the nuclei and
activation of CREB. Depletion of CREB by infection of cells with specific shRNA lentiviral particles attenuated both Tat-induced Rho
signaling and nuclear targeting of ZO-1. A decrease in CREB levels also attenuated Tat-induced endothelial and BBB hyperpermeability
as well as transendothelial migration of monocytic cells. The role of CREB in Tat-mediated alterations of ZO-1 was confirmed in brain
microvessels in mice with CREB shRNA lentiviral particles injected into the cerebral circulation. The present results indicate the crucial
role of Rho signaling and CREB in modulation of nuclear localization of ZO-1 and maintaining the integrity of endothelial monolayers.
Introduction
Disruption of endothelial tight junctions (TJs) is a feature of
several acute and chronic brain disorders, including infection by
human immunodeficiency virus-1 (HIV-1) (Dallasta et al., 1999;
Boven et al., 2000). Because endothelial cells are not productively
infected by HIV-1, several vascular effects of this virus are
thought to be mediated by secondary mediators, including the
HIV-1-specific protein Tat. Tat is taken up by the cells via inser-
tion into the endosomemembranes (Yezid et al., 2009), followed
by localization into the nuclei (De Marco et al., 2010). In addi-
tion, we demonstrated that Tat, in a dose-dependentmanner, can
interact with cellular receptors (e.g., vascular endothelial growth
factor receptor-2), activate small GTPases, and thus modulate TJ
protein expression (Andra´s et al., 2005; Zhong et al., 2008, 2010).
Tetraspan transmembrane proteins (e.g., occludin and clau-
dins) constitute the backbone of TJ strands, which are associated
with the actin cytoskeleton via several adaptor molecules, such as
zonula occludens-1 (ZO-1), ZO-2, and ZO-3. ZO proteins bind
directly to F-actin and other proteins that regulate cytoskeletal
dynamics (Schneeberger and Lynch, 2004). Indeed, depletion of
ZO-1 alters the dynamics of F-actin redistribution after a calcium
switch (McNeil et al., 2006) in Madin-Darby canine kidney
(MDCK) cells. However, the cellular role of ZO proteins appears
to bemuchmore complex than scaffolding functions at the junc-
tional sites and also involves intracellular signaling and gene ex-
pression. For example, ZO-2 was demonstrated to suppress gene
transcription by binding to the AP-1 transcription factor protein
complex (Betanzos et al., 2004; Bauer et al., 2010).
It has been recognized that the Rho signaling pathway has
modulatory effects on TJ integrity and endothelial barrier prop-
erties. For example, inhibition of Rho lowered permeability of
bovine microvascular endothelium (Carbajal and Schaeffer,
1999) and reduced baseline permeability of both post-capillary
venules in vivo and different cultured microvascular endothelial
cells in vitro (Adamson et al., 2002; Baumer et al., 2008). Conversely,
activation of RhoA downstream of several permeability-increasing
mediators, such as thrombin or TNF-, contributed to increased
endothelial permeability (Wojciak-Stothard and Ridley, 2002). In-
hibition of the Rho pathway in brainmicrovascular endothelial cells
alsoprotected againstmonocyte-inducedphosphorylationof occlu-
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din and claudin-5 and diminished transendothelial migration of
HIV-1-infectedmonocytes (Persidsky et al., 2006).
The cAMP response element-binding protein (CREB) is a
transcription factor activated by phosphorylation on Ser133. Recent
reports provide evidence that CREB can be involved in regulation of
epithelial junction function. Indeed, the transcriptional repression
of ZO-1 by JunD appears to be mediated through a CREB-binding
sitewithin theproximal regionof theZO-1promoter. In thepresent
study, we focused on the signaling and transcriptional mechanisms
that regulate nuclear targeting of ZO-1 by HIV-1 protein Tat. We
demonstrate that exposure to Tat induces nuclear localization via
activation of Rho signaling and activation of CREB binding to a
ZO-1 promoter in brain endothelial cells. Importantly, depletion of
CREBprotected both against Tat-induced alterations of ZO-1 levels
and disruption of endothelial integrity.
Materials andMethods
Cell cultures, infection with shRNA lentiviral particles, and Tat treatment.
Human brain cortical microvessel endothelial cells (hCMEC/D3) (Wek-
sler et al., 2005) were cultured as described previously (Zhong et al.,
2008). Before exposure to treatment factors, hCMEC/D3 cells were incu-
bated in EBM-2 medium without FBS and EGM-2 SingleQuots (Lonza)
for 24 h. For transendothelial migration studies, cocultures of hCMEC/D3
with humanmonocytic (THP-1) cells were used. THP-1 cells were cultured
in RPMI-1640medium supplemented with 10% FBS.
For specific experiments, hCMEC/D3 cells were infected with shRNA
lentiviral particles containing target-specific constructs encoding for
CREB-1 (h) shRNA and control shRNA (both from Santa Cruz Biotech-
nology) using the instructions of the manufacturer. This procedure re-
sulted in 50% decrease in CREB expression. Stable cell lines were
selected in amedium containing 10g/ml puromycin andmaintained in
the presence of puromycin in EBM-2 completed medium. The cells with
decreased CREB expression were fully viable.
HIV-1 Tat protein was purified as described by Ma and Nath (1997).
To determine specificity of Tat-induced effects, Tat solutions were im-
munoabsorbed using anti-Tat antibody conjugated to protein-A/G plus-
agarose (Santa Cruz Biotechnology), followed by centrifugation to
remove precipitated proteins. This antibody–absorption mixture was
named AA-Tat. Another control form of Tat was heat-inactivated Tat
(H-Tat) obtained by heating the protein at 90°C for 1 h, which inactivates
biological potentials of proteins but does not affect activity of endotoxins
such as LPS.
Adenovirus infection.Recombinant adenovirus encoding for green flu-
orescent protein (GFP) and the Rho inhibitor Clostridium botulinum
exoenzyme C3 transferase, the exoenzyme that specifically ribosylates
and inhibits the function Rho gene, was produced as described previ-
ously (Hirai et al., 2007) and named the C3 adenovirus. A separate ade-
novirus vector expressing GFP without exoenzyme C3 transferase was
constructed as a control (control adenovirus). The viruses were ampli-
fied by repeated infection into human embryonic kidney 293 cells.Media
containing recombinant adenoviruses were collected and stored at
80°C. hCMEC/D3 cells were infected with recombinant adenoviruses
at a multiplicity of infection of 200 in a 6 or 10 cm culture dish. Infection
with adenoviruses resulted in efficiency close to 100% as determined by
monitoring GFP signal under a fluorescent microscope.
Cell fractionation, immunoblotting, and electrophoretic mobility shift
assay. Cell fractions were obtained using a nuclear and cytoplasmic ex-
traction reagents kit from Thermo Fisher Scientific and analyzed by
Western blotting using standard approaches. The density of the bands
was calculated with the Scion Image program. CREB, phosphorylated
CREB (p-CREB) (Ser 133), phospho-myosin light chain 2 (MLC) (Ser 19),
andMLC2 antibodies were purchased fromCell Signaling Technologies.
RhoA, vascular endothelial (VE)-cadherin, and all secondary antibodies
were from Santa Cruz Biotechnology. ZO-1 and claudin-5 antibodies
were from Invitrogen. MLC kinase (MYLK) and anti-actin antibod-
ies were from Sigma.
For electrophoretic mobility shift assay (EMSA), synthetic oligonucle-
otides were produced and 5-biotinylated by Integrated DNA Technolo-
gies. The sequence for the wild-type CREB was 5CCG GGT GCC CAT
GAC GTC ATC ACC AGT TTC AGC 3 and for the mutant CREB was
5CCGGGTGCCCATGACGTCTACACCAGTTTCAGC3. Binding
reactions were performed using a LightShift Chemiluminescent EMSA
kit (Pierce) following the instructions of the manufacturer.
Integrity of hCMEC/D3monolayers and transendothelial migration. For
endothelial permeability and transendothelial migration measurements,
cells were cultured on 0.4 and 3.0 m Transwell inserts, respectively,
until confluency. The cells were treated with 100 nM HIV-1 Tat and
control Tat (AA-Tat or H-Tat) for 20 h. Endothelial permeability was
assessed by the flux of FITC–dextran 20 (molecular weight 20 kDa; 1
mg/ml; Sigma) across endothelial monolayers. For transmigration assay,
treated cells growing on the 3.0mmembrane inserts were placed in the
wells containing serum-free endothelial basal medium with added
CCL-2 (50 ng/ml) as chemoattractant. Monocytic THP-1 cells were
stained with calcein AM (5 M, for 25 min) and added in the amount of
5  105 on top of hCMEC/D3 monolayers for 4 h at 37°C. Florescence
was measured as a marker of THP-1 cell migration at 485 nm excitation
and 530 nm emission wavelengths.
Surgical procedures, animal treatment, and brain microvessel analyses.
All experimental procedures and protocols were reviewed and approved
by the Animal Care and Use Committee of the University of Kentucky.
C57BL/6J mice (10-week-old males) were injected with 40l of CREB-1
(m) shRNA or control shRNA lentiviral particles (1  106 infectious
units; both from Santa Cruz Biotechnology) into the internal carotid
artery (ICA) using a surgical technique described by our research group
(Chen et al., 2009). Forty-eight hours after lentiviral particle administra-
tion, Tat (50 g/mouse) was injected into the ICA. Brain microvessels
were isolated 24 h after Tat injection as described previously (Seelbach et
al., 2010). The obtained microvessels were either smeared on slides for
fluorescence microscopy analysis or resuspended in 0.5 ml of 6 M urea
lysis buffer containing 6 M urea, 0.1% Triton X-100, 10 mM Tris, pH 8.0,
5 mM MgCl2, 5 mM EDTA, and 150 mM NaCl with Complete Protease
Inhibitor for Western blot analyses. Integrity of the blood–brain barrier
(BBB) was measured 24 h after Tat injection as described previously
(Chen et al., 2009) by injecting 100 l of 2% sodium fluorescein (NaF)
into the ICA. Fifteenminutes after NaF injection, permeability across the
BBB was calculated as the ratio of fluorescence in the brain tissue to
plasma.
Statistical analysis. Each experiment was repeated a minimum of three
times. Data were expressed as mean SD. Statistical analysis was deter-
mined by using t test for two groups and one-way ANOVA to compare
mean responses among the treatments. Statistical probability of p 0.05
was considered significant.
Results
Rho signaling differentially regulates Tat-induced alterations
of total and nuclear ZO-1 expression
hCMEC/D3 cultures were treated with Tat for 15 h, and ZO-1
protein expression was evaluated in total cell lysates and nuclear
extracts by Western blotting. As indicated in Figure 1A, treat-
ment with Tat significantly decreased total ZO-1 levels in cells
that were mock infected or infected with a control adenovirus.
However, inhibition of Rho by adenovirus expressing exoenzyme
C3 transferase (C3 adenovirus) markedly protected against Tat-
induced alterations of ZO-1 levels. The observed effects were
specific because infection with control adenovirus did not affect
the basal levels of ZO-1. In addition, exposure to AA-Tat did not
affect ZO-1 levels. Expression of actin (housekeeping protein)
also was not affected by the infection procedure.
To further determine the relationship between the Rho signal-
ing and ZO-1 expression, ROCK (the Rho downstream kinase)
activity was inhibited by a 30 min pretreatment with Y27632
(4-[(1R)-1-aminoethyl]-N-pyridin-4-yl-cyclohexane-1-carbox-
amide) (5M). Similar to C3 adenovirus, treatment with Y27632
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significantly protected against a Tat-induced decrease of ZO-1
protein levels in total cell extracts (Fig. 1B).
We next evaluated the effects of Tat and Rho signaling on
ZO-1 levels in the nuclei of hCMEC/D3 cells. Although Tat treat-
ment decreased the total level of ZO-1, it exerted the opposite
effect on ZO-1 in nuclear fractions. As shown in Figure 1C, a 1 h
exposure to 100 nM Tat (but not AA-Tat) significantly increased
ZO-1 expression in nuclear fractions of
mock or control adenovirus-infected hC-
MEC/D3 cells. These effects were com-
pletely prevented by the inhibition of Rho
by C3 adenovirus (Fig. 1C) or inhibition
of ROCK by a 30 min pretreatment with
Y27632 (5 M) (Fig. 1D). It is now well
established that actin is present in the nu-
clei (Pederson, 2008) and its cytoplasmic
and nuclear pools are linked (Hofmann,
2009). Therefore, the levels of nuclear ac-
tin were detected as internal controls.
To determine the specificity of ZO-1
responses, we determined the effects of Tat
on cellular levels of VE-cadherin. hCMEC/
D3 cells were characterized by strong cy-
toplasmic VE-cadherin expression, with
virtually no presence in the nuclei. Tat ex-
posure did not affect cellular VE-cadherin
levels nor did it induce nuclear transloca-
tion of this protein (data not shown).
Tat simulates CREB phosphorylation
and binding activity
Because CREB might be involved in tran-
scriptional regulation of ZO-1 expression
(Chen et al., 2008), we next evaluated the
influence of Tat on CREB activation.
Treatment of hCMEC/D3 cultures with
Tat resulted in a time-dependent increase
in p-CREB as determined by Western
blotting. The most pronounced (2.7-
fold) induction of p-CREB levels was ob-
served after a 1 h exposure to 100 nM Tat.
Total CREB (t-CREB) levels did not
change in response to Tat (Fig. 2A). We
also evaluated CREB DNA binding activ-
ity using biotin-labeled oligonucleotide
probe with the sequence specific for the
CREB binding sites on ZO-1 promoter.
Exposure to 100 nM Tat induced a time-
dependent increase in CREB binding with
the maximum effect at 1 h of treatment.
The specificity of this effect was con-
firmedby a competition assay using a 100-
fold molar excess of unlabeled wild-type
or unlabeled mutated oligonucleotide
probes. The CREB binding signal disap-
peared in the presence of an excess of the
CREBwild-type competitor but was unaf-
fected in the presence of a mutated com-
petitor (Fig. 2B).
Tat induces the interactions between
the Rho and CREB pathways
To evaluate a possible interaction between
Rho signaling and CREB activity, a series of immunoprecipita-
tion studies was performed using anti-CREB antibody. As
indicated in Figure 3A, CREB immunoprecipitatedwith p-CREB,
RhoA,MLC, andMYLK, a downstreamkinase fromRho. Impor-
tantly, treatment with 100 nM Tat for 1 h markedly increased
these interactions, reflecting increased phosphorylation of
CREB and activation of the Rho pathway.
Figure 1. Rho signalingmodulates Tat-induced alterations of total and nuclear expression of ZO-1. A, C, hCMEC/D3 cultures at
50% confluence were infected with C3 adenovirus (Ad-C3) or control adenovirus (Ad-con). Two days after infection, cells were
exposed to 100 nM Tat and ZO-1 protein levels were measured by immunoblotting in total cell lysates after treatment for 15 h (A)
or nuclear extracts after treatment for 1 h (C). For control experiments, themock- or adenovirus-infected cellswere incubatedwith
100 nM Tat for 15 h. B, D, Confluent hCMEC/D3 cultures were pretreated with Y27632 (5M; ROCK inhibitor) for 30 min and then
exposed to Tat (100 nM). ZO-1 levels were detected in whole-cell lysates after a 15 h exposure (B) or in nuclear extracts after a 1 h
exposure (C) by immunoblotting. ZO-1 expression was normalized to actin levels. The blots reflect representative data from three
different experiments (mean SD), and the bar graphs are quantified data from these experiments. *p 0.05, **p 0.01 or
***p 0.001, comparedwith the respective control (vehicle-treated cells). ††p 0.01 or †††p 0.001, data in cultures exposed
to Tat plus C3 adenovirus are significantly different fromTat plusmock infection or Tat plus control adenovirus. ###p 0.001, data
in cultures exposed to Tat plus Y27632 are significantly different from those in cultures exposed to Tat alone.
Figure2. Tat stimulates CREB phosphorylation and binding activity. Time-dependent effects of Tat on phosphorylation of CREB
(A) and DNA binding activity (B). Cells were exposed to 100 nM Tat for the indicated time points. A, p-CREB was determined by
immunoblottingwith specific anti-phospho-CREB (Ser 133) antibody, and the levelswere normalized to t-CREB levels.B, CREBDNA
binding activitywas analyzed by EMSA. Competition studywas performedby adding 100-foldmolar excess of unlabeledwild-type
CREBprobe (the lanebefore last) or unlabeledmutatedprobe (last lane). First lane (Neg), nuclear proteinwas not added to binding
reaction. The images are representative blots, and the bar graphs are pooled densitometry data from three experiments (mean
SD). **p 0.01, compared with vehicle-treated cells.
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We then evaluated the involvement of Rho signaling in Tat-
induced CREB DNA binding by blocking Rho pathways via in-
fecting hCMEC/D3 cells with C3 adenovirus. Control cells were
mock infected or infected with the control adenovirus. The cul-
tures were then exposed to Tat for 1 h and CREB binding was
determined in the nuclear proteins. As indicated in Figure 3B,
treatment with Tat significantly increased CREB binding ac-
tivity in control cultures. However, this effect was markedly
attenuated by infection with C3 adenovirus. Tat-induced
CREB binding was also prevented by pretreatment with ROCK
inhibitor Y27632 (5 M for 30 min) (data not shown). Finally,
pretreatment with Y27632 or with MYLK inhibitor ML-9 [1-
(5-chloronaphthalene-1-sulfonyl)-1H-hexahydro-1,4-diazepine]
completely abolished Tat-mediated phosphorylation of CREB (Fig.
3C,D, respectively).
Next, we studied the influence of CREB on Rho signaling.
Cellular CREB levels were depleted by infecting hCMEC/D3
cells with specific CREB shRNA lentiviral particles, whereas
control cultures were infected with control shRNA lentivirus.
This procedure resulted in an50% decrease in cellular CREB
(data not shown). Importantly, CREB depletion inhibited Tat-
mediated phosphorylation of MLC (Fig. 3E), indicating the
dependency of the Rho pathway on CREB levels. Thus, the
results in Figures 3 and 4 indicate that the Rho cascade closely
interacted with CREB, resulting in cross-activation of these
signaling pathways.
CREB activity is required for Tat-induced nuclear targeting
of ZO-1
Because inhibition of the Rho pathway protected against Tat-induced
nuclear localization of ZO-1 (Fig. 1C,D) andRho closely interacts
with CREB (Fig. 3), we next addressed the role of CREB in Tat-
induced elevation of nuclear ZO-1 levels. The experiments were
performed on hCMEC/D3 cells in which CREB was depleted by
infection with specific CREB shRNA lentiviral particles. Consis-
tent with the results shown in Figure 1, a decrease in total ZO-1
levels was observed in control cultures exposed to 100 nM Tat for
15 h (Fig. 4A); however, a 1 h Tat treatment caused an increase in
nuclear ZO-1 (Fig. 4B). Importantly, depletion of CREB fully
abolished these effects in both total cell lysates and nuclear
fraction.
To further link these findings with CREB activation, we deter-
mined the effects of Tat on CREB phosphorylation and binding
activity in control and CREB-depleted hCMEC/D3 cells. Using
conditions established in experiments reflected in Figure 3, cells
were treated with 100 nM Tat for 1 h. Tat-induced phosphoryla-
tion of CREB was completely inhibited in CREB-depleted cells
(Fig. 4C). Similarly, Tat-stimulated CREB DNA binding activity
Figure 3. Tat-induced Rho signaling and CREB activation are cross-dependent. A, CREB coimmunoprecipitates with Rho kinases. Confluent hCMEC/D3 cells were treated with 100 nM Tat for 1 h,
and cell lysates containing the same amounts of proteinswere immunoprecipitated using anti-CREB antibody, followed by determination of p-CREB, RhoA,MLC, andMYLK by immunoblotting.WB,
Westernblot.B, hCMEC/D3 cellswere infectedwithC3or control adenovirus (Ad-C3andAd-con, respectively) as in Figure1A. Then, the cellswere treatedwith100nMTat for 1h, andnuclear proteins
were analyzed for CREB DNA binding by EMSA. Specificity of the binding reaction was determined by adding an excess of unlabeled probe (the lane before last) or mutated probe (last lane). C,
Subconfluent hCMEC/D3 cells were pretreatedwith Y27632 (5M) for 30min and then exposed to Tat (100 nM) for 1 h. CREB phosphorylation was detected by immunoblotting as in Figure 2A and
normalized to actin levels. D, Subconfluent hCMEC/D3 cells were pretreated with the indicated doses of ML-9 (MLCK inhibitor) for 30 min and then exposed to Tat (100 nM) for 1 h. CREB
phosphorylation was detected by immunoblotting and normalized to t-CREB levels. E, Cellular CREBwas depleted by infecting hCMEC/D3 cells with specific CREB shRNA (CREB-sh). Control cultures
were infected with control shRNA lentiviral particles (Control-sh). The cells were then treated with Tat (100 nM) for 1 h, followed by determination of total and phosphorylated MLC by immuno-
blotting. t-CREB was determined to indicate cellular CREB depletion. The blots reflect representative data from four to five different experiments, and the bar graphs represent quantified results
(mean SD) from these experiments as analyzed by densitometry. *p 0.05 or **p 0.01, comparedwith the respective control (vehicle-treated cells). †††p 0.001, data in cultures exposed
to Tat plus C3 adenovirus are significantly different fromTat plusmock infection or Tat plus control adenovirus. #p0.05, ##p0.01, or ###p0.001, data in cultures treatedwith Tat plus Y27632
or Tat plus ML-9 are significantly different from those in cultures treated with Tat alone.
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to oligonucleotide probes with the binding sequences specific for
ZO-1 promoter was abolished in nuclear fractions of CREB-
depleted hCMEC/D3 cells (Fig. 4D).
Tat-induced alterations of ZO-1 expression are attenuated by
CREB depletion in an animal model
The role of CREB in Tat-induced alteration of ZO-1 expression
was evaluated in mouse brain capillaries. Administration of Tat
to control shRNA-injected mice resulted in a decrease in immu-
noreactivity and fragmentation of staining continuity for ZO-1.
Importantly, these effects were abolished inCREB-depleted brain
microvessels (Fig. 5A). Densitometric quantification of Western
blots confirmed that Tat-mediated diminished levels of ZO-1
proteinwere statistically significant in brainmicrovessels isolated
fromCREB-depletedmice comparedwith controls (Fig. 5B). The
blots in Figure 5B confirm that injections with CREB shRNA
lentiviral particles into the ICA effectively depleted CREB in
brain microvessels. In addition, CREB depletion protected
against Tat-induced disruption of the BBB integrity (Fig. 5C).
CREB depletion protects again Tat-induced disruption of the
endothelial barrier function
The final series of experiments determined the effects of CREB
depletion on the functional status of endothelial monolayers. As
indicated in Figure 6A, treatment with Tat (but not with AA-Tat
andH-Tat) disrupted the endothelial bar-
rier function as illustrated by increased
FITC–dextran 20 flux across cultured hC-
MEC/D3 monolayers. Importantly,
CREB depletion by infecting the cells with
CREB shRNA lentiviral particles signifi-
cantly protected against these effects,
mimicking in vivo results presented in
Figure 5C. Similarly, CREB depletion
completely protected against Tat-induced
adhesion of monocytic cells to endothelial
monolayers (Fig. 6B).
Discussion
Disruption of the integrity of the brain en-
dothelium is well documented in HIV-1
infection. Clinical studies have reported
the absence or fragmentation of ZO-1 and
occludin in HIV-positive patients with
encephalitis or HIV-1-associated demen-
tia (Dallasta et al., 1999; Boven et al., 2000;
Eugenin et al., 2006). To confirm the role
of TJs in HIV-1-associated brain pathol-
ogy, it has been shown that monocyte
migration occurs between endothelial-cell
borders and TJ disruption, correlated with
the intensity ofmonocyte infiltration in hu-
man brain tissue with HIV encephalitis
(Persidsky et al., 2006). In addition, mono-
cyte infiltrationhas been associatedwith the
disruption of ZO-1 immunoreactivity in
HIV-positive patients (Boven et al., 2000).
HIV-1 protein Tat has been shown to alter
theexpressionof severalTJproteins, includ-
ing occludin, claudin-5, ZO-1, and ZO-2
(Zhong et al., 2008). However, there is no
information available on the effects of
HIV-1 and/or HIV-1-specific proteins on
nuclear localization of TJ proteins and on
the regulatory mechanisms that control such localization.
Although HIV-1 has been shown to decrease cellular expres-
sion of ZO-1 in vitro and in an animal model (Luabeya et al.,
2000; Huang et al., 2009), novel results of the present study indi-
cate that this effect is accompanied by a significant increase in
nuclear levels of ZO-1. Moreover, inhibition of Rho signaling by
C3 transferase or Y27632 protected against Tat-mediated altera-
tions of nuclear localization of ZO-1. These results are in agree-
ment with our previous report that Tat is a potent stimulator of
Rho signaling in brain endothelial cells (Zhong et al., 2010). In
addition, our findings are consistent with reports indicating a
critical role of Rho in the regulation of TJ protein expression and
TJ disassembly through activation of signaling pathways that reg-
ulate cytoskeletal organization.
Indeed, RhoA activation can reduce the endothelial barrier
function via inactivation of MLC phosphatase (MLCP), leading
to increasedMLC phosphorylation and actin–myosin contractil-
ity (Itoh et al., 1999; Stamatovic et al., 2003). RhoA activation also
results in the formation of stress fibers composed of filamentous
actin and myosin II (Ridley and Hall, 1992; Wo´jciak-Stothard et
al., 1998; Etienne-Manneville and Hall, 2002). Such mechanisms
may contribute, at least in part, to an impaired intracellular
movement of ZO-1 and contribute to increased levels of this TJ
protein in the nuclear fractions of Tat-stimulated hCMEC/D3
Figure 4. CREB activity is required for Tat-induced nuclear targeting of ZO-1. Cellular CREB was depleted as in Figure 3D,
followed by treatment with Tat (100 nM) for 15 h (A) or 1 h (B–D). ZO-1 was determined in total cell lysates (A) and in nuclear
fraction (B). The levels of p-CREB were determined by immunoblotting in total cell lysates (C) and CREB DNA binding activity was
measured by EMSA (D). Specificity of DNA binding was determined by adding a 100-fold excess of unlabeled probe. ZO-1 expres-
sion was normalized to actin levels, and p-CREB expression was normalized to t-CREB levels. The blots reflect representative data
from three to four different experiments, and the bar graphs represent quantified results (mean SD) from these experiments as
analyzed by densitometry. *p 0.05 or **p 0.01, compared with the respective control (vehicle-treated cells). †p 0.05,
††p 0.01, or †††p 0.001, data in cultures exposed to Tat plus CREB shRNA lentiviral particles are significantly different
compared with Tat plus control shRNA.
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cells (Fig. 7). In support of this notion, it
was demonstrated that cytochalasin B,
which interferes with actin polymeriza-
tion and contractile microfilaments, in-
hibited ZO-2 migration to the nuclei in
MDCK monolayers (Islas et al., 2002).
HIV-1 and Tat protein were shown to in-
duce matrix metalloproteinase (MMP) and
proteasome activities, which in turn cande-
grade TJ proteins, including ZO-1
(Huang et al., 2009). Inhibition of both
MMP and proteasome activity resulted in
attenuation of HIV-1-induced altered ex-
pressionofZO-1 (Huanget al., 2009).Thus,
nuclear translocation may protect this pool
of ZO-1 against proteolytic degradation,
whereas the membrane pool remains vul-
nerable to MMP and proteasome proteoly-
sis. Because membrane ZO-1 is the major
formof thisTJprotein, its decrease results in
diminished levels of total ZO-1 (Fig. 7).
In the present study, inhibition of Rho
activity protected against Tat-induced al-
terations of the total and nuclear ZO-1
levels. In search for a possible target in-
volved in such a protection, we focused on
the role of CREB. The rationale for such
studies was based on the literature reports
indicating that CREB may act as an impor-
tant trans-factor in regulation of TJ protein
expression (Lui et al., 2007). Indeed, com-
putational analysis revealed that ZO-1-
promoter contains several potential CREB
binding sites (Chen et al., 2008). The role of
CREB in ZO-1 expression was also con-
firmed by demonstrating that transcription
factor JunD inhibitedTJ proteinZO-1 tran-
scription through binding to the CREB
binding site at the ZO-1 promoter (Chen et
al., 2008).
CREB is activated through Ser133 phos-
phorylation, and our data indicate that
exposure to Tat both stimulates phos-
phorylation of CREB and activates its
DNA binding activity (Fig. 3). These ob-
servations are in agreement with reports
that Tat can activate CREB in various cell
types, including monocytes and neuronal
cells (Williams et al., 2005). Literature
data suggest that Tat-induced activation
of CREB may be mediated via calmodulin/
CaMKII-dependent p38 MAPK. In addi-
tion, intracellular Tat has been shown to
phosphorylate CREB-1 through regula-
tion of the ERK1/2MAPKpathway (Gee et al., 2006, 2007). In the
present study, we showed that Tat-mediated CREB activation
was abolished by C3 adenovirus and ROCK inhibitor Y27632.
Another potential mechanism of CREB phosphorylationmay in-
volve MLCP. In fact, we recently published that Tat-induced ac-
tivation of RhoA can inhibit MLCP via phosphorylation of
myosin phosphatase target subunit 1 and increased phosphory-
lation of MLC. Thus, phosphorylation of CREB appears to be
placed directly downstream of RhoA. In support of this hypoth-
esis, we demonstrated that CREB immunoprecipitates with
MYLK (Fig. 3A) and inhibition of MYLK by ML-9 protected
against Tat-induced phosphorylation of CREB (Fig. 3D).
To further evaluate the involvement of CREB in Tat-
mediated alterations of ZO-1 expression, CREB was depleted
from hCMEC/D3 cells by infection with lentiviral particles
containing CREB-specific shRNA. Unexpectedly, depletion of
CREB prevented Tat-induced phosphorylation of MLC (Fig.
3E), a downstream kinase in the Rho signaling, indicating that
Figure 5. CREBmodulates Tat-induced alteration of ZO-1 expression in vivo. Mice were injectedwith CREB shRNA (CREB-sh) or
control shRNA (Control-sh) lentiviral particles into the ICA for 48 h, followed by Tat injection (50g/mouse). Brain microvessels
were isolated from the ipsilateral hemisphere 24 h after Tat administration. A, CREB depletion protected against Tat-induced
fragmentation of ZO-1 immunoreactivity (red staining). DAPI staining was performed to visualize the nuclei (blue staining). B,
Immunoblotting analysis of ZO-1 and CREB expression. The blots are representative images from three to four mice and the
quantified results are depicted in the form of bar graphs. Note also a marked decrease in CREB expression in microvessels of CREB
shRNA-treatedmice.C, CREBdepletionprotectedagainst Tat-induceddisruptionof theBBB integrity. **p0.01, compared to the
respective control. ##p 0.01 data in the group Tat plus CREB shRNA lentiviral particles are significantly different comparedwith
Tat plus control shRNA.
Figure 6. Depletion of CREB expression attenuates Tat-mediated increase in permeability and monocyte migration across
endothelial monolayers. Cellular CREB was depleted as in Figure 3D, followed by treatment with Tat (100 nM), AA-Tat, or H-Tat
(both negative controls) for 20 h.A, Endothelial permeabilitywas determined bymeasuring the flux of FITC–dextran ofmolecular
weight 20 kDa across hCMEC/D3 monolayers grown on 0.4 M membranes. B, For monocyte transendothelial migration, hC-
MEC/D3 cells were grown on 3.0Mmembrane inserts. Before treatment with Tat, 5 105 calcein AM-stainedmonocytic THP-1
cells were added on the top of confluent CREB-depleted and control shRNA-infected hCMEC/D3 monolayers for 4 h at 37°C.
Florescencewasmeasured as amarker ofmonocytic cell migration. ***p 0.001, comparedwith the respective control (vehicle-
treated cells) at. ††p 0.01 or †††p 0.001, data in cultures exposed to Tat plus CREB shRNA lentiviral particles are significantly
different compared with Tat plus control shRNA.
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activation of downstream Rho mediators is dependent on
CREB. Thus, our novel results suggest that activation of Rho
and CREB are interrelated and regulate in concert ZO-1 ex-
pression in response to Tat treatment (Fig. 7). The role of
CREB in Tat-mediated alterations of ZO-1 protein was also
confirmed in vivo by depletion of this transcription factors
from brain microvessels.
Although nuclear localization of TJ proteins has been rec-
ognized, its biological significance remains elusive. Neverthe-
less, evidence indicates that TJ proteins, such as ZO-1 or ZO-2,
have functions beyond regulation of endothelial permeability
and are also involved in intracellular signaling and gene
expression. For example, ZO proteins can associate with reg-
ulatory molecules (e.g., with adapter proteins, signaling mol-
ecules, or growth factors), thereby modulating the cell cycle.
ZO proteins exhibit domains, such as several nuclear localiza-
tion and nuclear export signals, enabling them to shuttle be-
tween the cytoplasm and the nucleus. There is no information
available on the role of ZO-1 in the nuclear fraction; however,
it might at least partially overlap with that of ZO-2. Literature
reports indicate that the ratio between the amount of ZO-2
localizing at TJ and the amount of nuclear ZO-2 adds an ad-
ditional variable in the control of epithelial cell proliferation
and differentiation. Indeed, several studies have suggested that
the nuclear localization of ZO-2 depends on the state of cell–
cell contacts in epithelial monolayers.
ZO-2 was found to localize at the nucleus primarily in
subconfluent epithelial cells before maturation of TJs but
gradually exits the nucleus in a leptomycin-sensitive way when
the monolayer reaches confluence. Nuclear accumulation of
ZO-2 is also believed to be a general response of epithelial and
endothelial cells to environmental or mechanical stress be-
cause it can be induced by impairing cell– cell contacts by
mechanical injury. Transient nuclear expression of ZO-2 has
also been observed after heat shock and chemical insults in
cerebral endothelial cells and kidney epithelial and endothelial
cells (Islas et al., 2002; Traweger et al., 2003). Results of the
present study demonstrate that CREB depletion prevents Tat-
induced nuclear accumulation of ZO-1 and at the same time
attenuates Tat-stimulated endothelial hyperpermeability and
enhanced monocyte migration (Fig. 5). Thus, targeting of
ZO-1 into the nuclei has profound effects on the functional
status of brain endothelial cells.
In summary, the results of the present study demonstrate
that exposure to HIV-1 protein Tat results in a decrease in
total cellular levels of ZO-1 and an increase in nuclear levels of
this TJ protein. Mechanistically, stimulation of Rho signaling
and activation of CREB appear to be responsible for triggering
nuclear accumulation of ZO-1. Preventing nuclear accumula-
tion of ZO-1 by depletion of CREB attenuated Tat-induced
dysfunction of endothelial barrier. Overall, these results indi-
cate the importance of small GTPase, such as Rho, in regula-
tion of TJ protein expression, localization, and modulation of
the brain endothelial integrity in the context of HIV-1 brain
infection.
Figure 7. The proposed signaling pathway of Tat-induced nuclear localization of ZO-1 in human brain endothelial cells. HIV-1 protein Tat activates RhoA and downstream ROCK kinase, leading
to phosphorylation of MLC, which then can mediate cross-linking F-actin into stress fibers and influence nuclear ZO-1 translocation. Stimulation of the Rho pathway results in phosphorylation of
CREB, a transcriptional activator of ZO-1. In addition, exposure to HIV-1 or Tat protein stimulatesMMPs and proteasome,which are responsible for degradation of TJ proteins, including ZO-1 (Huang
et al., 2009). Nuclear translocation may protect this pool of ZO-1 against proteolytic degradation, whereas the membrane pool remains vulnerable to MMP and proteasome proteolysis. Because
membraneZO-1 is themajor formof this TJ protein, its decrease results indiminished levels of total ZO-1. In addition to stimulationof CREBphosphorylationby theRho signaling, CREBalso influences
activation of MLC, indicating a close crosstalk between these two signaling pathways.
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